within Pharmacolibrary.Drugs.ATC.V;

model V08CX01
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 1.8333333333333335e-06,
    adminDuration  = 600,
    adminMass      = 3400 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00013000000000000002,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>V08CX01</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Perflubron (perfluorooctyl bromide) is a radiocontrast agent formerly used in diagnostic imaging, particularly as a contrast medium for magnetic resonance imaging (MRI) and computed tomography (CT). It is a fluorinated, inert compound that enhances imaging quality. Perflubron is no longer widely approved or used in current practice.</p><h4>Pharmacokinetics</h4><p>No published peer-reviewed pharmacokinetic studies are available for perflubron as an imaging agent in humans; pharmacokinetic parameters below are estimated based on animal studies, the physicochemical properties of perfluorocarbon compounds, and limited human imaging reports.</p><h4>References</h4><ol><li><p>Noveck, RJ, et al., &amp; Woods, CM (2000). Randomized safety studies of intravenous perflubron emulsion. II. Effects on immune function in healthy volunteers. <i>Anesthesia and analgesia</i> 91(4) 812–822. DOI:<a href=&quot;https://doi.org/10.1097/00000539-200010000-00009&quot;>10.1097/00000539-200010000-00009</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11004031/&quot;>https://pubmed.ncbi.nlm.nih.gov/11004031</a></p></li><li><p>Leese, PT, et al., &amp; Keipert, PE (2000). Randomized safety studies of intravenous perflubron emulsion. I. Effects on coagulation function in healthy volunteers. <i>Anesthesia and analgesia</i> 91(4) 804–811. DOI:<a href=&quot;https://doi.org/10.1097/00000539-200010000-00008&quot;>10.1097/00000539-200010000-00008</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11004030/&quot;>https://pubmed.ncbi.nlm.nih.gov/11004030</a></p></li><li><p>Spahn, DR, &amp; Kocian, R (2005). Artificial O2 carriers: status in 2005. <i>Current pharmaceutical design</i> 11(31) 4099–4114. DOI:<a href=&quot;https://doi.org/10.2174/138161205774913354&quot;>10.2174/138161205774913354</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16378514/&quot;>https://pubmed.ncbi.nlm.nih.gov/16378514</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end V08CX01;
